UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats

Journal of allergy and clinical immunology, 1998-10, Vol.102 (4), p.571-578

1998

Volltextzugriff (PDF)

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Annals of oncology, 2004-12, Vol.15 (12), p.1825-1833

2004

Volltextzugriff (PDF)

Treatment of cat allergy with T-cell reactive peptides

American journal of respiratory and critical care medicine, 1996-12, Vol.154 (6 Pt 1), p.1623-1628

1996

Volltextzugriff (PDF)

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

International journal of gynecological cancer, 2005-11, Vol.15 (6), p.1023-1034

2005

Volltextzugriff (PDF)

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Clinical and experimental allergy, 2011-10, Vol.41 (10), p.1400-1413

2011

Volltextzugriff (PDF)

Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial

Journal of allergy and clinical immunology, 1995-05, Vol.95 (5), p.923-932

1995

Volltextzugriff (PDF)

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc epsilon RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Clinical and experimental allergy, 2011-10, Vol.41 (10), p.1400-1413

2011

Volltextzugriff (PDF)

Effects of peptide therapy on ex vivo T-cell responses

Journal of allergy and clinical immunology, 1998-04, Vol.101 (4), p.506-513

1998

Volltextzugriff (PDF)

Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to IL-10

The Journal of immunology (1950), 1993-09, Vol.151 (6), p.3206-3214

1993

Volltextzugriff (PDF)

Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma

Journal of allergy and clinical immunology, 1995-08, Vol.96 (2), p.174-181

1995

Volltextzugriff (PDF)

The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells

The Journal of biological chemistry, 1992-07, Vol.267 (19), p.13558-13563

1992

Volltextzugriff (PDF)

In vivo Leukocytes Labeling Using a Platelet Factor 4–Derived Heparin Binding Peptide Technetium Complex

International archives of allergy and immunology, 1999-02, Vol.118 (2-4), p.362-363

1999

Volltextzugriff (PDF)

Molecular Cloning of a cDNA that Encodes the Peptide Core of a Mouse Mast Cell Secretory Granule Proteoglycan and Comparison with the Analogous Rat and Human cDNA

Proceedings of the National Academy of Sciences - PNAS, 1989-05, Vol.86 (10), p.3763-3767

1989

Volltextzugriff (PDF)

Mouse mast cells that possess segmented/multi-lobular nuclei

Blood, 1997-07, Vol.90 (1), p.382-390

1997

Volltextzugriff (PDF)

Clinical and immunologic effects of component peptides in Allervax Cat

International archives of allergy and immunology, 1997-01, Vol.113 (1-3), p.224-226

1997

Volltextzugriff (PDF)

Characterization of the human gene that encodes the peptide core of secretory granule proteoglycans in promyelocytic leukemia HL-60 cells and analysis of the translated product

The Journal of biological chemistry, 1990-04, Vol.265 (10), p.5889-5896

1990

Volltextzugriff (PDF)

Cloning and Characterization of the Mouse Gene That Encodes the Peptide Core of Secretory Granule Proteoglycans and Expression of This Gene in Transfected Rat-1 Fibroblasts

The Journal of biological chemistry, 1989-10, Vol.264 (28), p.16719-16726

1989

Volltextzugriff (PDF)

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer

Journal of immunotherapy, 2009-01, Vol.32 (1), p.54-65

2009

Volltextzugriff (PDF)

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

International journal of gynecological cancer, 2005-11, Vol.15 (6), p.1023-1034

2005

Volltextzugriff (PDF)

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

Journal of immunotherapy, 2008-02, Vol.31 (2), p.207-214

2008

Volltextzugriff (PDF)

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

Journal of clinical oncology, 2004-09, Vol.22 (17), p.3507-3516

2004

Volltextzugriff (PDF)

Continuous Release of Secretory Granule Proteoglycans From a Cell Strain Derived From the Bone Marrow of a Patient With Diffuse Cutaneous Mastocytosis

Blood, 1992-01, Vol.79 (1), p.144-151

1992

Volltextzugriff (PDF)

Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.5507-5507

2008

Volltextzugriff (PDF)

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Clinical and experimental allergy, 2011-10, Vol.41 (10), p.1400

2011

Volltextzugriff (PDF)

Final follow up survey of the randomized Pbo-controlled study of oregovomab (Ov) as a consolidation treatment for advanced ovarian cancer (OC): Insights into surveillance approaches

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.5079-5079

2006

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(47)
Humans
(46)
Biological And Medical Sciences
(32)
Animals
(25)
Female
(24)
Medical Sciences
(23)
Adult
(15)
Male
(15)
Middle Aged
(15)
Immunology
(14)
Immunotherapy
(13)
Mice
(13)
Oncology
(12)
Aged
(10)
Allergy
(10)
Antibodies, Monoclonal - Therapeutic Use
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)
Ovarian Neoplasms - Immunology
(10)
Pharmacology. Drug Treatments
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Treatment of cat allergy with T-cell reactive peptides

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc epsilon RI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Effects of peptide therapy on ex vivo T-cell responses

Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to IL-10

Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma

The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells

In vivo Leukocytes Labeling Using a Platelet Factor 4–Derived Heparin Binding Peptide Technetium Complex

Molecular Cloning of a cDNA that Encodes the Peptide Core of a Mouse Mast Cell Secretory Granule Proteoglycan and Comparison with the Analogous Rat and Human cDNA

Mouse mast cells that possess segmented/multi-lobular nuclei

Clinical and immunologic effects of component peptides in Allervax Cat

Characterization of the human gene that encodes the peptide core of secretory granule proteoglycans in promyelocytic leukemia HL-60 cells and analysis of the translated product

Cloning and Characterization of the Mouse Gene That Encodes the Peptide Core of Secretory Granule Proteoglycans and Expression of This Gene in Transfected Rat-1 Fibroblasts

The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

Continuous Release of Secretory Granule Proteoglycans From a Cell Strain Derived From the Bone Marrow of a Patient With Diffuse Cutaneous Mastocytosis

Evaluation of maintenance mono-immunotherapy to improve outcomes in advanced ovarian cancer (OV CA)

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity

Final follow up survey of the randomized Pbo-controlled study of oregovomab (Ov) as a consolidation treatment for advanced ovarian cancer (OC): Insights into surveillance approaches

Suchergebnisse filtern